| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 291.3MM | +56% |
| Gross Profit | 136.4MM | - |
| Cost Of Revenue | 155MM | +57% |
| Operating Income | -183.6MM | +46% |
| Operating Expenses | 319.9MM | - |
| Net Income | -178.4MM | +36% |
| R&D | 164.7MM | +55% |
| G&A | 155.2MM | +44% |
| Interest Expense | 4.1MM | +44% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Catalysts lie ahead for both of these companies.
In this article, we will take a detailed look at the 12 Most Shorted Stocks in 2024. For a quick overview of such stocks, read our article 5 Most Shorted Stocks in 2024. Short-sellers may be annoying for corporations (and Redditors?), but investors usually find themselves thanking these companies for doing the often back-breaking and excruciating research that […]
Believes the two new nominated directors possess the necessary experience to tackle the underperformance of the business which will improve its share price Shah Capital which owns 6.7% of Novavax, in a letter to the board says that the low share price reflects the board and management’s failure to capitalize on Novavax’s many significant competitive advantages and TAM opportunities The letter highlights that the underperformance is self-inflicted and is the result of reactive leadership and outd
Novavax shareholder Shah Capital is pushing the vaccine maker to add two of its nominees to the board to help tackle "underperformance" at the company and improve its share price. The hedge fund nominated Suresh Katta, founder and CEO of biotech firm Saama, and Venkat Peri, CEO of Quantiva Health, to Novavax's eight-member board, saying the duo had the experience in setting the company's strategic direction.
Who wins this face-to-face between two beaten-down biotechs?
Is there still too much risk surrounding this business?
To extend its existing cash runway and curb cash burn, Novavax (NVAX) initiates multiple restructuring initiatives that are aimed at lowering operating expenses and enhancing profitability.
The 2024 presidential election is shaping up to be just as exciting and contentious the 2020 contest. That’s because it looks to be a rematch between President Biden and former President Trump. There’s a wildcard thrown in this time with Robert Kennedy Jr. running an independent campaign that could pull voters from both sides. The stock market went on a rollercoaster ride four years ago. A decade-long bull market was brought up short by the pandemic. The S&P 500 lost one-third of its value in a
(Bloomberg) -- A former Phlow Corp. executive and his cousin admitted to insider trading on confidential information about a pandemic-related government loan to Eastman Kodak Co. Most Read from BloombergA Million Simulations, One Verdict for US Economy: Debt Danger AheadTSMC Facilities to Resume Production Overnight After QuakeTrump Media’s Business Doesn’t MatterKim Jong Un Faces Annihilation in Most Korea War ScenariosTrump Got His $175 Million Bond From a Billionaire Fan’s CompanyAndrew Stile